psoriasis vulgaris psoriasis vulgaris,
Conditions
Interventions
will start with 10 mg subcutaneous injection/week and the dose of methotrexate will increase to 15,
and then 25 mg/week every 4-
week visit if PASI 75 does not achieve,will start with 10 mg subcutaneous injection/week and the dose of methotrexate will increase to 15,
week visit if PASI 75 does not achieve
Active Comparator Drug,Active Comparator Drug
oral administration of methotrexate ,subcutaneous injection methotrexate
Sponsors
Faculty of Medicine
Department of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Entry criteria require a clinical diagnosis of psoriasis vulgaris in patients who had the Psoriasis Area Severity Index (PASI) score > 10 or body surface area (BSA) involvement >10% or who had PASI score <10 or BSA < 10% but did not respond to topical treatment and being at least 18 years of age
Exclusion criteria
Exclusion criteria: Exclusion criteria include pregnant or lactating women, known hypersensitivity to methotrexate, patients with malignancy or HIV-infection or hepatitis B or C infection, tuberculosis, and abnormal liver or kidney or hematologic function. All patients will have a 12-week washout of any systemic therapies including systemic corticosteroid, methotrexate, cyclosporine, acitretin, other immunosuppressive drugs, biologics and phototherapy for psoriasis prior to receiving the study drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement at week 4, 8, 12, 16, 20, 24, amd 28 Psoriasis Area Severity Index (PASI) score | — |
Secondary
| Measure | Time frame |
|---|---|
| patient's satisfaction at week 4, 8, 12, 16, 20, 24, amd 28 visual analog scale (VAS) method | — |
Contacts
Public ContactCharoen Choonhakarn
Khon Kaen University
Outcome results
None listed